Early-Stage lung blood pressure drug trial halted

NCT ID NCT05339087

Terminated Disease control Sponsor: Heidelberg University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either riociguat or a placebo for 24 weeks. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Riociguat (oral tablet)
What this could lead to: If successful, this could point toward a treatment option for early-stage pulmonary hypertension, potentially slowing disease progression.
What could go wrong: This trial was terminated early with only 35 participants, so results are limited. Riociguat may not show benefit or could cause side effects like low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OTHER SYSTEMIC INVOLVEMENT OF CONNECTIVE TISSUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

connective tissue disorder Familial Primary Pulmonary Hypertension idiopathic pulmonary arterial hypertension pulmonary hypertension systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OTHER SYSTEMIC INVOLVEMENT OF CONNECTIVE TISSUE PRIMARY PULMONARY HYPERTENSION PULMONARY VASCULAR DISORDER SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Carl Gustav Carus University Hospital at the TU Dresden, Medical Department I, Center for PH

Dresden, Germany
Centre de référence des Maladies Auto-Immunes Systémiques rares du Nord et Nord-Ouest (CeRAINO) Service de Médecine Interne et Immunologie Clinique Hôpital Claude Huriez, CHU

Lille, 59037, France
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital Heidelberg

Heidelberg, 69126, Germany
LKH-Univ. Klinikum Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Pulmonologie

Graz, 8036, Austria
Ordensklinikum Linz GmbH Elisabethinen

Linz, 4020, Austria
Royal Free London NHS Foundation Trust

London, United Kingdom
Università Degli Studi Di Napoli Federico II Scuola Di Medicina E Chirurgia

Naples, 80131, Italy
Universitätsspital Zürich Pulmonale Hypertonie, Klinik für Pneumologie

Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.